Clinical trials: Diffuse Intrinsic Pontine Glioma
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
DIPG, Brain Tumor, Pediatric, Recurrent
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Although many children with brain tumours are successfully cured of their disease, a substantial proportion of patients suffer disease recurrence and require further treatment.
- Conditions
- DIPG, Brain Tumor, Pediatric, Recurrent, Brain Tumor, DIPG, Radiation Toxicity
- Trial name
- NCT04670016
- Testing
- This study does not include an intervention.
- Where
- 13 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt.
- Conditions
- Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma
- Trial name
- NCT04185038
- Testing
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Seattle Children's Hospital
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
The goal of this study is to evaluate the safety of the study drug PTC596 (Unesbulin) taken in combination with radiotherapy (RT) when given to pediatric patients newly diagnosed with High-Grade Glioma (HGG) including diffuse…
- Trial name
- NCT03605550
- Testing
- PTC596, Radiotherapy
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nationwide Children's Hospital
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given.
- Trial name
- NCT04655404
- Testing
- Larotrectinib, Larotrectinib surgical
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 15 people
- Sponsor
- Nationwide Children's Hospital
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB.
- Trial name
- NCT04943848
- Testing
- rHSC-DIPGVax, Balstilimab, Zalifrelimab
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Diffuse Intrinsic Pontine Glioma
Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma
The aim of the study is to determine the safety of Cilengitide in combination with radiation therapy.
- Trial name
- CILENT (NCT01165333)
- Testing
- Cilengitide dose escalation, Cilengitide, Concomitant radiotherapy
- Where
- 9 sites in France
- Volunteers
- 32 people
- Sponsor
- Centre Oscar Lambret
Relapsed Solid Tumor, Refractory Solid Tumor
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did…
- Trial name
- NCT04238819
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
FUS Etoposide for DMG
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor. Focused Ultrasound (FUS) using microbubbles and neuro-navigator controlled sonication is a non-invasive method of temporarily opening…
- Trial name
- NCT05762419
- Testing
- Etoposide; Oral, 50 Mg, Focused ultrasound with neuro-navigator-controlled sonication
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
High Grade Gliomas, Atypical Teratoid Rhabdoid Tumors (ATRT)
Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor
In this study, we want to find out more about the side effects of an investigational drug for relapsed or refractory atypical teratoid rhabdoid tumor and high-grade glioma, Gallium Maltolate (GaM) and what doses of GaM are safe…
- Conditions
- High Grade Gliomas, Atypical Teratoid Rhabdoid Tumors (ATRT), Diffuse Midline Glioma, DIPG
- Trial name
- GABRIEL (NCT07331064)
- Testing
- Gallium maltolate
- Volunteers
- 15 people
- Sponsor
- Sarah Rumler
Glioblastoma, Medulloblastoma
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses.
- Conditions
- Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT04049669
- Testing
- Indoximod, Partial Radiation, Full-dose Radiation
- Where
- 5 sites in United States
- Volunteers
- 130 people
- Sponsor
- Theodore S. Johnson
Glioblastoma Multiforme, Anaplastic Astrocytoma
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma
- Trial name
- NCT05956821
- Testing
- SIACI of cetuximab and bevacizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Miami
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
The standard of care for children with DIPG includes focal radiotherapy (RT) but outcomes have remained dismal despite this treatment.
- Trial name
- BRAVO (NCT03396575)
- Testing
- TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Doctors and other medical scientists want learn about the biology of DIPG/DMG and to develop better ways to diagnose and treat patients with DIPG/DMG.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma
- Trial name
- NCT03101813
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diffuse, Intrinsic Pontine Glioma
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Current therapies for diffuse, intrinsic pontine glioma (DIPG) provide very limited benefit to the patient. The rationale for the use of Antineoplaston therapy in this protocol study derives from experience with subjects from…
- Trial name
- NCT02742883
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Burzynski Research Institute
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas
Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor. Focused Ultrasound (FUS) using microbubbles and neuro-navigator-controlled sonication is a non-invasive method of temporarily opening…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- NCT04804709
- Testing
- Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Diffuse Intrinsic Pontine Glioma
Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma
Diffuse intrinsic pontine gliomas (DIPGs), which diffusely occupy the pons of brainstem, are the deadliest primary brain cancer in children.
- Trial name
- ENACTING (NCT04749641)
- Testing
- Histone H3.3-K27M Neoantigen Vaccine Therapy
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yang Zhang